10-Q: Fortrea Holdings Inc. Reports Q2 2024 Results: Revenue Declines Amid Restructuring

Fortrea Holdings Inc. experienced a revenue decrease of 8.6% in the second quarter of 2024, alongside a net loss of $138.4 million, as the company continues to restructure its operations.

Summary

• Fortrea Holdings Inc. reported a revenue of $662.4 million for the three months ended June 30, 2024, which is an 8.6% decrease compared to the $725.1 million reported for the same period in 2023.
• The company's revenue for the six months ended June 30, 2024, was $1,324.5 million, a 6.7% decrease from the $1,419.0 million reported for the same period in 2023.
• The decrease in revenue was primarily due to a decrease in organic revenue of 8.3% for the three months ended June 30, 2024 and 6.6% for the six months ended June 30, 2024, driven by lower service revenues and decreased pass through revenues.
• The company reported a net loss of $138.4 million for the three months ended June 30, 2024, compared to a net income of $30.8 million for the same period in 2023.
• For the six months ended June 30, 2024, the company reported a net loss of $239.4 million, compared to a net income of $43.3 million for the same period in 2023.
• Selling, general and administrative expenses increased by 59.7% for the three months ended June 30, 2024 and 28.8% for the six months ended June 30, 2024, primarily due to incremental costs incurred to exit the Transition Services Agreement with Labcorp.
• The company incurred $10.4 million in restructuring charges for the three months ended June 30, 2024 and $13.7 million for the six months ended June 30, 2024, as part of its efforts to reduce overcapacity and align resources.
• The company sold its Enabling Services Segment during the second quarter of 2024 for estimated proceeds of $281.6 million, recognizing a loss on disposal of $23.2 million.
• As of June 30, 2024, the company's backlog was $7.4 billion.
• The company entered into a three-year $300.0 million accounts receivable securitization program on May 6, 2024, selling $300.0 million of receivables with net proceeds of $297.9 million.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to declining revenues, a significant net loss, and increased expenses. While the company is taking steps to restructure and manage its finances, the overall sentiment is weak due to the poor financial results and ongoing challenges.

Positives

• The company established a new $300 million accounts receivable securitization program, which provided net proceeds of $297.9 million.
• The company is actively implementing a comprehensive remediation plan to address material weaknesses in internal controls over financial reporting.
• The company believes its existing cash and cash flows generated from operations, plus existing credit facilities, will be sufficient to cover the needs of its current and planned operations for at least the next 12 months.

Negatives

• The company experienced a significant decrease in revenue, with an 8.6% drop in Q2 2024 compared to Q2 2023.
• Fortrea reported a net loss of $138.4 million in Q2 2024, a substantial decline from the net income of $30.8 million in Q2 2023.
• Selling, general and administrative expenses increased significantly, by 59.7% in Q2 2024, due to costs associated with exiting the Transition Services Agreement with Labcorp.
• The company recognized a loss on disposal of $23.2 million from the sale of its Enabling Services Segment.
• The company identified material weaknesses in its internal controls over financial reporting that have not yet been remediated.

Risks

• The company may not realize all of the benefits expected from the Spin-Off, or such benefits may be delayed.
• The company relies on Labcorp for certain services, and the transition to independence may be costly and time-consuming.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is exposed to risks associated with international operations and currency fluctuations.
• The company is subject to customer and therapeutic area concentrations.
• A further deterioration in the macroeconomic environment could lead to defaults or cancellations by customers.
• The company's backlog and net new business may not grow as anticipated, and such measures may not be indicative of future revenues.
• The company may underprice contracts, overrun cost estimates, or experience delays in change orders.
• The company may not realize the full purchase price and benefits of the disposition of its Endpoint and Patient Access businesses.

Future Outlook

The company expects restructuring actions to continue throughout 2024 and believes its existing cash and cash flows generated from operations, plus existing credit facilities, will be sufficient to cover the needs of its current and planned operations for at least the next 12 months.

Management Comments

• The company leverages its global scale, clinical data insights, scientific expertise, technology innovation, industry network and decades of experience as a standalone company and as a business unit prior to the Spin to deliver tailored solutions to its customers.
• With what the Company believes is a distinctive market offering, Fortrea meets growing global demand for clinical development services.

Industry Context

The document indicates that Fortrea is operating in a growing global market for clinical development services, which is a competitive and highly regulated industry. The company is positioning itself to meet the growing demand for these services through its flexible delivery models and global scale.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, the reclassification of information technology costs and certain facility costs to Selling, general and administrative expenses was made to improve comparability of costs against peer companies in the clinical research industry.
• The document does not mention specific competitors or benchmarks, making it difficult to assess Fortrea's performance relative to industry standards.

Legal Proceedings

• The Company is involved from time to time in various claims and legal actions arising in the ordinary course of business.
• The Company does not believe that any liabilities related to such claims and legal actions will have a material effect on its financial condition, results of operations or cash flows.

Related Party Transactions

• Direct costs include costs incurred from related parties of $27.0 and $48.8 during the three and six months ended June 30, 2023, respectively.
• The combined statements of operations for prior periods also include costs for certain centralized functions and programs provided and administered by Labcorp that were allocated to Fortrea.
• The company has entered into several agreements with Labcorp that govern the relationship of the parties following the Separation, including the Separation and Distribution Agreement, the Tax Matters Agreement, the Employee Matters Agreement, and the Transition Services Agreement with Labcorp.

Stakeholder Impact

• Shareholders are negatively impacted by the reported net loss and declining revenues.
• Employees may be affected by the ongoing restructuring and potential job losses.
• Customers may experience changes in service delivery as the company restructures.
• Suppliers and creditors may be impacted by the company's financial performance and restructuring efforts.

Next Steps

• The company expects restructuring actions to continue throughout 2024.
• The company will continue to monitor the financial performance of and assumptions for its reporting units.
• The company will continue to review, optimize and enhance its financial reporting controls and procedures.

Key Dates

Keywords

contract research organization, clinical trials, biopharmaceutical, medical device, revenue, net loss, restructuring, spin-off, backlog, accounts receivable, securitization, internal controls, financial performance